Biocardia, Inc. company information, Employees & Contact Information

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 GlobeNewswire

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results Yahoo Finance

Cardiovascular Cell Therapy Updates: BioCardia CEO to Present Three Clinical Programs at NYC Conference Stock Titan

BioCardia Releases Primary Endpoint Results of Open Label Roll-in Cohort of CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial Diagnostic and Interventional Cardiology

BioCardia Phase 3 CARDIAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years HMP Global Learning Network

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter GlobeNewswire

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure Yahoo Finance

82% Reduction in Angina Episodes: BioCardia's Cell Therapy Shows Promising Results in Heart Disease Trial Stock Titan

BioCardia Reveals Plans to Request Meeting With FDA Regarding CardiAMP Heart Failure Cell Therapy CGTLive®

178 Patient Trial Data: BioCardia's Breakthrough Cell Therapy for Heart Failure Advances in Japan Stock Titan

BioCardia, Inc. Completes Consultation with Japan's PMDA on BCDA-01 for Ischemic Heart Failure Treatment Quiver Quantitative

Cardiovascular Therapeutics Developer BioCardia Successfully Maintains Nasdaq Capital Market Listing Stock Titan

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes Diagnostic and Interventional Cardiology

Cellular Therapeutics Pioneer BioCardia Announces Q2 2025 Earnings and Pipeline Update Stock Titan

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure Diagnostic and Interventional Cardiology

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure Diagnostic and Interventional Cardiology

BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family Diagnostic and Interventional Cardiology

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval Diagnostic and Interventional Cardiology

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach Diagnostic and Interventional Cardiology

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership Diagnostic and Interventional Cardiology

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application Diagnostic and Interventional Cardiology

BioCardia's Revolutionary Heart Failure Treatment Advances Toward FDA Approval: Key Timeline Released Stock Titan

$12 Million Capital Raise: BioCardia Secures Funding for Cardiovascular Therapeutics Development Stock Titan

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction Diagnostic and Interventional Cardiology

CardiAMP, a Heart Failure Cell Therapy, Misses Mark in Phase 3 Trial HCPLive

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected Diagnostic and Interventional Cardiology

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting Diagnostic and Interventional Cardiology

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study Stock Titan

BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy Fierce Biotech

BCDA - BioCardia Reports First Quarter 2025 Business Highlights and Financial Results ADVFN

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up ADVFN

BioCardia Announces Clinical Leadership Changes GlobeNewswire

BioCardia Executives Increase Their Stakes in the Company TradingView

BioCardia Initiates Commercial Release of Avance Steerable Introducer Diagnostic and Interventional Cardiology

Biocardia Receives FDA Clearance for Avance Steerable Introducer Family Diagnostic and Interventional Cardiology

BCDA Stock Price and Chart — NASDAQ:BCDA TradingView

Regenerative player BioCardia reverse merges to back PhIII in heart failure Fierce Biotech